top of page

Nelson Advisors: The $25M to $250M European HealthTech, MedTech, Health AI, Digital Health Exit Playbook

Writer: Nelson Advisors
Nelson Advisors
2 minutes ago
13 min read
Nelson Advisors: The $25M to $250M European HealthTech, MedTech, Health AI, Digital Health Exit Playbook
Nelson Advisors: The $25M to $250M European HealthTech, MedTech, Health AI, Digital Health Exit Playbook

Most HealthTech exits between $25M and $250M of enterprise value are won or lost long before a buyer sees a teaser. The price is set by what diligence finds, and what diligence finds is set by the 18 months of preparation that came before it.


Founders often treat a sale as an event. They hire an adviser, build a data room in six weeks, and hope the story carries the numbers. In this size range it rarely does.


A $40M digital health company does not have the finance team, legal function or regulatory department of a $2Bn strategic. Yet the buyer's diligence team will ask the same questions of both. The gaps that a large company closes as routine become, for a smaller one, price chips, escrows, earn-outs or a broken deal.


The good news is that almost every one of those gaps is fixable with time. An unassigned patent, a missing technical file, a revenue recognition policy that will not survive an audit, a single customer at 40% of revenue: none of these is fatal at month 18. All of them are expensive at month one.


Our Nelson Advisors playbook sets out what to fix and when, across the four areas where lower-to-mid-market HealthTech, MedTech, Digital Health and Health AI deals most often lose value: financials, intellectual property, regulatory files and customer concentration. It ends with the final six months, when preparation turns into a process.


The market you are selling into


Buyers in 2026 are writing bigger cheques for fewer companies, which raises the bar for every asset that comes to market.


Mergermarket data shows European healthcare M&A value rose 56% to EUR 40bn in the first half of 2026, on a lower deal count. Strategic acquirers outpaced financial sponsors over the same period (Mergermarket).


Valuations tell the same story of selectivity. Our own analysis found average European HealthTech revenue multiples fell from a 6.5x peak in 2023 to 4.8x in early 2025 (Nelson Advisors). The average hides a wide spread. Clean, well-prepared assets clear well above it, and assets with open questions sit well below.


Three consequences follow for a founder planning an exit in 2028.


  • Diligence is deeper. Buyers concentrating capital into fewer deals spend more on each one. Expect a quality of earnings review, a technical and AI audit, a regulatory audit and customer calls as standard.

  • Strategics set the pace. A corporate acquirer integrates what it buys. It cares about IP ownership, regulatory status and contract assignability more than a sponsor running a standalone platform might.

  • Private equity still matters. Sponsors accounted for roughly a third of global healthtech transactions in early 2026 (Nelson Advisors). They price on EBITDA quality and cash conversion, so the finance workstream below applies to them with full force.


In this market, preparation is a pricing input. The same business, with the same revenue, can attract materially different offers depending on how much risk the buyer has to underwrite.


The 18 Month timeline at a glance


The workstreams overlap by design. Financials and customer concentration start first because they take longest to show up in the numbers; IP and regulatory fixes follow; the final six months belong to the sale process itself.


Months 18–12: Financials


Start with the numbers, because a buyer's first model is built on them and every later conversation is anchored to it.


Get audited. Many companies in this range have never had a full audit, or have had one under a small-company exemption. Aim to reach the market with at least two audited years. An audit started at month 18 gives you a clean prior year and time to fix what the auditors find.


Fix revenue recognition before someone else does. HealthTech revenue is rarely simple. A single contract can bundle a software licence, implementation, hardware, training and support. Decide how each element is recognised, document the policy, and apply it consistently across both audited years. A buyer's accountants restating your revenue mid-process is one of the fastest ways to lose a headline price.


Define recurring revenue honestly. Separate contracted recurring revenue from pilots, grants, one-off implementation fees and innovation funding. Buyers pay a recurring multiple only for revenue that recurs. If you include a paid pilot in ARR and the buyer strips it out, you lose both the revenue and your credibility.


Build the KPI pack buyers expect. At a minimum, produce monthly history for 24 to 36 months of:


  • ARR or contracted revenue, split by product and geography

  • Gross and net revenue retention, by customer cohort

  • Gross margin by revenue line, with hosting and clinical staff costs allocated properly

  • Customer acquisition cost and payback period

  • Cash conversion and debtor days, which matter where public health systems pay slowly


Prepare a defensible adjusted EBITDA. List every adjustment, with evidence. Founder salaries should be restated at market rate. Capitalised development costs need a clear policy, because a buyer will test whether your EBITDA is flattered by capitalisation.


Close the month properly. Management accounts should be produced within 10 to 15 working days and reconcile to the audited figures. A buyer will track your monthly trading throughout the process. Slow or inconsistent reporting reads as weak control.


Normalise working capital. The buyer will set a working capital target from your trailing average. Clean up aged debtors, deferred revenue schedules and supplier terms now, so the average reflects a well-run business.


Clear the tax file. Review R&D tax relief claims, VAT treatment of healthcare services, employee share option valuations, contractor employment status and any inter company pricing between group entities. Tax exposures usually end up as specific indemnities or retentions. Most can be resolved in advance at modest cost.


Set a budget you will beat. The 12 months before launch become the forecast base. Missing your own budget during a sale process hands the buyer a reason to reprice. Hitting it, quarter after quarter, is the strongest support a forecast can have.


Months 15–9: Intellectual property


A buyer is paying for technology it must be certain you own. In a strategic-led market, a gap in the chain of title can stop a deal outright.


Trace the chain of title. List everyone who has ever written code, designed hardware or developed algorithms for the company. That includes founders before incorporation, employees, contractors, offshore development shops and clinical advisers. Each one needs a signed assignment of IP to the company. Chasing a former contractor for a signature takes weeks at month 15 and can be impossible, or expensive, once they know a sale is live.


Check the institutional strings. Many European HealthTech companies began in a university, a hospital or a grant-funded consortium. Review spin-out licences, hospital co-development agreements and grant terms for ownership claims, revenue shares, exploitation obligations or consent rights on a change of control. Renegotiate where you can, while you still have time and no buyer is waiting.


Tidy the registered rights. Confirm patents, trade marks and domains are registered in the company's name, in force, and filed in the markets a buyer will care about. Trade marks registered to a founder personally are a common and avoidable finding.


Run an open source audit. Commission a software composition scan and produce a bill of materials. Look for copyleft licences in code you distribute or serve, and remediate. Buyers run these scans as standard, so it is better to find the problem yourself.


Document your AI data rights. For Health AI companies this is now the centre of IP diligence. Be ready to show, for every model in production:


  • Where the training data came from, and under what licence or data sharing agreement

  • Whether patient data was used, on what legal basis, and whether those rights survive a sale

  • Whether customer contracts permit you to train on customer data, and who owns the resulting model improvements

  • Which third-party foundation models you depend on, and on what commercial terms

  • How datasets, model versions and validation results are recorded


A model trained on data you had no clear right to use is an asset a buyer cannot safely acquire. If the position is unclear, fix it by re-papering agreements or, in the worst case, retraining.


Evidence your security posture. Complete an independent penetration test and close its findings. Bring certifications such as ISO 27001 up to date, along with any national health-system requirements you sell under. A security incident log with clear root-cause records is better than a claim of no incidents with nothing to support it.


Months 12–6: Regulatory files


Regulatory status is the area where European HealthTech deals differ most from ordinary software deals, and where buyers have become least forgiving.


Confirm what your product is. Write down the intended purpose of each product and test it against your marketing claims. Software that claims to diagnose, predict or guide treatment is very likely a medical device, whatever the company has assumed. A mismatch between claims and classification is a finding in almost every regulatory audit.


Know your MDR position and deadline. Legacy devices relying on the extended transition must hold MDR certification by 31 December 2027 for class III and class IIb implantables, and by 31 December 2028 for other classes (Dutch Health and Youth Care Inspectorate). Those dates now fall inside a typical buyer's first years of ownership. If you are still on a legacy certificate, a buyer will want to see a signed notified body agreement and a credible project plan.


Do not plan around the MDR revision. A proposal to revise the MDR and IVDR is in progress, with a European Parliament vote expected in the first quarter of 2027 and adoption targeted for the second or third quarter (Emergo by UL). Current rules apply until then. Buyers value the certificates you hold today.


Bring the files up to date. The buyer's regulatory adviser will ask for:


  • Technical documentation for each device, current to the released software version

  • Quality management system records, including the latest ISO 13485 audit report and open non-conformities

  • Clinical evaluation reports and the evidence behind them

  • Post-market surveillance plans, complaint logs and vigilance reports

  • Certificates, registrations and agreements with your authorised representatives in each market


The most common gap is drift. The product has moved on through dozens of releases and the technical file describes a version from two years ago.


Take a position on the EU AI Act. The Digital Omnibus on AI, published in July 2026 as Regulation (EU) 2026/1744, pushed the high-risk obligations for AI in regulated products such as medical devices back to 2 August 2028 (Cooley). The delay helps, but an acquirer in 2028 inherits the obligation on day one. Prepare a short classification memo, a gap analysis against the high-risk requirements, and a costed plan to close it.


Put data protection in order. Health data is special category data, and buyers treat GDPR findings seriously. Have your records of processing, impact assessments, processor agreements, international transfer mechanisms and breach log complete and current.


Have an answer on the European Health Data Space. The regulation applies generally from 26 March 2027, and the first obligations for electronic health record systems follow on 26 March 2029 (Taylor Wessing). If your product is, or exchanges data with, an EHR system, a buyer will ask for your interoperability roadmap.


Evidence market access. Reimbursement listings, health technology assessments and procurement framework positions are regulatory assets too. Record when each one expires or comes up for renewal, because a buyer will.


Months 18–6: Customer concentration


Concentration is the one problem on this list that paperwork alone cannot fix, which is why it needs the full 18 months.


A business with one customer at 40% of revenue is, to a buyer, a business whose value depends on a contract the buyer does not control. The usual responses are a lower price, a large earn-out tied to that customer's renewal, or a decision not to bid.


Measure it the way a buyer will. Calculate the revenue share of your top one, five and ten customers. Then repeat the exercise by ultimate payer. Ten hospital contracts under a single regional framework, or twenty clinics reached through one distributor, are one concentration risk, not many. Do the same for channel partners and geography.


There is no fixed threshold, but a common rule of thumb is that questions start when a single customer passes 15% to 20% of revenue, and deal structures change materially beyond 30%.


Diversify with intent. Eighteen months is enough to change the mix if you direct sales effort at it. Prioritise new logos over upsell to your largest account, and consider whether a second geography or customer segment can reach meaningful scale before launch. Growth that lowers concentration is worth more than the same growth that raises it.


Lengthen and strengthen the contracts you have. Where you cannot reduce a customer's share, reduce the risk attached to it.


  • Renew early and move key accounts onto multi-year terms

  • Negotiate out termination-for-convenience rights where you can

  • Review every material contract for change-of-control and assignment clauses, and seek waivers or amendments well before a process

  • Convert pilots and rolling arrangements into signed contracts

  • Add price indexation where contracts are silent


Watch the tender calendar. In public health systems, contracts end and are re-procured on a fixed timetable. Launching a sale six months before your largest contract is re-tendered invites the buyer to wait for the result or price in the loss. Time your process to follow a major renewal, not precede it.


Prepare your references. Buyers will ask to speak to your largest customers late in the process. Strong relationships at several levels of each key account, and a customer who can describe measurable outcomes, turn a concentration risk into evidence of product value.


Look at the other side of the ledger. Dependence on one cloud provider, one component supplier or one EHR vendor's integration programme is concentration too. Document the terms and the fallback.


Months 6–0: Preparing to launch


The last six months convert a well-prepared company into a well-run process. By now the clean-up should be finished, and the work shifts to presentation, buyers and people.


Months to launch

Focus

What gets done

6–5

Vendor due diligence

Commission sell-side financial, tax, legal and regulatory reports. Fix what they find.

5–4

Equity story

Build the information memorandum, financial model and management presentation.

4–3

Buyer universe

Map strategics, sponsors and cross-border acquirers. Begin quiet pre-marketing conversations.

3–2

Data room

Populate and index the room. Stage sensitive material for later rounds.

2–1

People and shareholders

Agree management incentives, align the board, rehearse the team.

0

Launch

Approach buyers with a clear timetable and a complete first-round pack.


Invest in vendor due diligence. A sell-side quality of earnings report costs money, and it pays for itself. It lets you find and explain issues on your own terms, shortens the buyer's work, and makes it harder to reopen price late in the process. For regulated products, a short independent regulatory review does the same job.


Build the equity story on evidence. The strongest memoranda in this sector lead with clinical and economic outcomes, then show how those outcomes produce retention and growth. Every claim should trace to a document in the data room.


Think widely about buyers. The natural acquirer may not be the obvious competitor. Consider EHR and healthcare IT vendors, MedTech groups adding software, pharma services businesses, payers and providers, and sponsor-backed platforms building by acquisition. US and Asian acquirers looking for a European footprint belong on the list.


Align shareholders early. Confirm that the cap table is accurate, that drag-along rights work as intended, and that investors agree on timing and price expectations. A preference stack that leaves management with little at the likely price needs to be addressed before launch, because the buyer will ask how the team is being retained.


Protect the business. A sale process consumes management time for months. Decide who runs the company while the chief executive and finance lead are in buyer meetings. Trading performance during the process is the single most watched number.


Six mistakes that cost founders value


  1. Starting when an offer arrives. An inbound approach feels like a shortcut. Without preparation, it leaves you negotiating with one buyer, on their timetable, with your gaps exposed.

  2. Counting non-recurring revenue as recurring. Buyers always find it, and they discount everything else you have told them.

  3. Assuming the software is not a medical device. The assumption is usually years old and has not been tested against current claims or current rules.

  4. Leaving contractor IP unassigned. It is the cheapest problem to fix early and one of the most expensive to fix late.

  5. Selling ahead of a major renewal. The buyer will price the risk of loss in full and give little credit for the likelihood of a win.

  6. Letting the business drift during the process. A missed quarter in the middle of diligence costs more than any finding in the data room.


Start the clock now


If you expect to sell in 2028, the 18-month clock starts in the first half of 2027. For some workstreams, such as an MDR transition or a serious concentration problem, it has already started.


None of this work is wasted if you decide not to sell. Audited accounts, clean IP, current regulatory files and a balanced customer base make a company easier to finance, easier to partner with and easier to run. They also mean that when the right buyer does call, you can say yes from a position of strength.


Nelson Advisors works with founders, boards and investors in European HealthTech, MedTech, Digital Health and Health AI on exactly this preparation, and on the sale processes that follow. If an exit is on your horizon, we would be glad to talk through where you stand against this timeline.


Sources



Nelson Advisors > European Healthcare Technology Investment Banking


Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk


Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital 


Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb 



Nelson Advisors LLP


Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT




Meet Nelson Advisors @ Events in 2026


Digital Health Rewired > March 2026 > Birmingham, UK  


NHS ConfedExpo  > June 2026 > Manchester, UK 


HLTH Europe > June 2026, Amsterdam, Netherlands


HIMSS AI in Healthcare > July 2026, New York, USA


Bits & Pretzels > September 2026, Munich, Germany  


HealthInvestor Healthcare Summit > September 2026, London, UK 


World Health Summit 2026 > October 2026, Berlin, Germany


HLTH USA 2026 > October 2026, USA


Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia


Web Summit 2026 > November 2026, Lisbon, Portugal  


MEDICA 2026 > November 2026, Düsseldorf, Germany


Leaders in Health Summit 2026 > November 2026, London, UK 


Venture Capital World Summit > December 2026, Toronto, Canada


Meet Nelson Advisors @ Events in 2027


Digital Health Rewired > March 2027 > Birmingham, UK


Barclays Health Elevate > March 2027, London, UK 


NHS ConfedExpo  > June 2027 > Manchester, UK 


HLTH Europe > June 2027, Amsterdam, Netherlands


Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk


Comments


Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page